Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Lung Cancer. 2016 Nov 9;103:6–10. doi: 10.1016/j.lungcan.2016.11.005

Table 1.

Eligibility criteria for STARS and ROSEL. [8,9].

Trial name Inclusion Criteria Exclusion Criteria
STARS

  • Histologic or cytologic confirmation of NSCLC

  • Clinically staged as T1N0M0 or T2 (≤4cm)N0M0

  • PET/CT with no clinically positive nodes

  • FEV1> 40% predicted, postoperative FEV1>30% predicted, and DLCO >40% predicted

  • ≥18 years of age

  • Zubrod 0-2

  • Primary tumor >4cm

  • Neuroendocrine tumor

  • Evidence of regional or distant metastasis

  • Previous lung radiation

  • Pregnancy

  • Severe vascular, cerebrovascular, or heart disease
ROSEL

  • Either histologic/cytologic confirmation of NSCLC or evidence of a new or growing pulmonary lesions with radiologic features which is PET-avid

  • Clinical Stage IA tumor with no evidence of regional or distant metastases

  • Tumor is at least 2cm away from main and lobar bronchi, and at least 1.5cm away from aorta and main pulmonary artery

  • ECOG performance score ≤2

  • History of any active malignancy (other than NSCLC) unless treated > 3 years with no evidence of recurrence or is non- melanoma skin cancer or in- situ cervical cancer

  • Unstable comorbidities (congestive heart failure, myocardial infarction in the past year)

  • Pregnancy